基于CARD/1平台的公路三维动画设计与开发

针对目前广泛使用的三维动画制作方法耗时耗力的缺点,本文研究了用CARD／1进行三维动画的设计与开发,介绍了基于CARD／1平台的公路三维动画设计与开发的一些关键技术。初步实践表明,这种方法为实现公路设计的三维可视化提出了一种简单易行的思路。     

1,6-二磷酸果糖在冠脉搭桥术中对心肌的保护作用

目的评估1,6-二磷酸果糖(fructose-1,6-diphosphate,FDP)在冠状动脉搭桥术中对心肌的保护作用。方法随机选取30例冠心病患者,分为实验组和对照组,每组15例。实验组于术前三天及手术当日给予FDP,对照组给予生理盐水。分别于麻醉诱导后(T0),再灌注后1 h(T1)、4 h(T2)、24 h(T3)及48 h(T4),测定血浆肌钙蛋白I(cardiactroponin I,cTnI)、肌酸激酶同工酶(creatine kinase MB,CK-MB)、超氧化物歧化酶(superoxide dismutase,SOD)及丙二醛浓度(malondiadehyde,MDA)。结果实验组于T1、T2、T3三个时点CK-MB及cTnI浓度均显著低于对照组(P<0.05),T1及T2两个时点MDA浓度明显低于对照组(P<0.05)。结论FDP能够减轻由脂质过氧化反应介导的心肌缺血再灌注损伤,有助于缺血再灌注后心功能的恢复及改善。     

HSV—1在小鼠体内的感染与分布

实验选用BALB/c小鼠作为感染对象,经腹腔接种10 LD_(50)HSV-10.3ml,24h内即可出现病毒血症,并持续到小鼠死亡。同时在肝、脾分离到病毒,48h后在肺、肾组织中分离到病毒,120h后在脑组织中分离到病毒。所分离的病毒经免疫荧光,ELISA法检测确属HSV-1。感染小鼠均在120h～144h内全部死亡,死前有麻痹等脑炎症状。电镜下可见脑组织有炎性病理变化,并在细胞内。外找见典型的HSV颗粒。     

PDCD5基因在初诊Graves'病患者PBMCs中表达情况的初步研究

目的探讨促凋亡基因PDCD5 mRNA在初诊Graves'病(GD)患者外周血单个核细胞(PBMCs)中的表达。方法半定量RT-PCR法检测53例初诊GD患者外周血单个核细胞PDCD5 mRNA表达的阳性率和表达水平。结果35例PDCD5 mRNA在GD患者PBMCs中表达呈阳性,阳性率为66.1%,较正常对照者(55.6%)升高;其表达水平(1.01±0.13)显著高于正常对照(0.52±0.13,P<0.05),且GD患者高T3水平组PDCD5 mRNA的表达显著高于低T3水平组(P<0.05)。结论PDCD5 mRNA在GD患者PBMC表达升高,可能与GD淋巴细胞凋亡异常有关。     

基于灰色模型和指数平滑法的集装箱吞吐量预测

提出了在灰色模型GM(1,1)和三次指数平滑法基础上的组合预测方法。集装箱吞吐体系是一个灰色系统,因此可以通过灰色系统进行建模并预测其吞吐量,通过对宁波港历年集装箱吞吐量的观察,发现其吞吐量呈持续的曲线增长趋势,因此考虑采用三次指数平滑法进行预测,在灰色GM(1,1)和三次指数平滑法的基础上采用了加权组合预测的方法,对宁波港今后几年的集装箱吞吐量进行了预测.     

车身一体化涂装的应用研究

为实现涂装生产中"高质量、低成本、高效率及环境友好"的目的,文中以溶剂型钻石银灰金属漆车身涂装为例,比较了不同工艺和不同面漆的涂层性能,探讨了对现行车身涂装工艺进行创新的可行性。     

应用电子技术专业"2+1工学结合"模式的研究和实践

本文通过对应用电子技术专业的研究、探索和实践,总结出“2＋1工学结合”的高职教育模式。此模式对三年制的高等职业教育分为二个教学阶段。第一个阶段是学生在校进行必要的理论学习和专业技能训练,第二个阶段是到企业进行一年的顶岗实习。有“三个观念”要改变：一是教师的传统教学思想和教学方法要改变;二是传统的培养目标和教学计划要改变;三是学生理想的就业观念要改变。     

The effect of prostaglandin E1 on recovery of early renal graft functions after transplantation

Objective To investigate the effect of prostaglandin E: (PGE1) on recovery of early renal graft functions after transplantation. Methods One hundred and seven patients after renal transplantation were allocated in the treated group, and treated by conventional treatment with injection of 10 μg prostaglandin E1 additionally twice a day for 14 days. And eighty-eight patients who received conventional treatment alone after renal transplantation at the corresponding period were allocated in the control group. Indexes of the two groups, including incidence of delayed graft function and acute rejection reaction, volume of urine, serum certaintie (SCr), endogenous certainties clearance rate (CCr), the blood flow resistance in graft as well as blood viscosity (BV), and platelet aggregation rate (PAR), were determined. Results The urinary volume and endogenous certainties clearance rate of the treated group were significantly higher, but the level of SCr, incidence of renal function recovery retardation, BV, PAR and blood flow resistance in graft were significantly lower than these of the control group (P<0.05). The difference of incidence of acute rejection reaction between the two groups was insignificant (P>0.05). Conclusion Prostaglandin E1 can improve blood microcirculation and decrease the incidence of renal function recovery retardation. These effects are helpful for recovery of renal function after renal transplantation.     

Construction and identification of recombination expression vector Ksp-Cadherin-Gpx1-Kik1

Objective To construct and identify the Gpx1-Klk1 vector which contains kidney-specific promoter (Ksp-cadherin). Methods Through PCR amplification, the human Gpx1, Klk1, and Ksp-cadherin eDNA were obtained by taking Gpx1 cDNA, Klk1 eDNA, and Ksp-cadherin BAC as templates. After being testified, the PCR products were inserted into the expressive vector pIRES-EGFP step-by-step to produce a recombinant vector Ksp-cadherin-Gpx1-Klk1. This vector was examined by restriction enzyme digestion and sequence analysis. Results The recombinant expressive vector Ksp-cadherin-Gpx1-Klk1 was successfully constructed. Conclusion The construction of the recombinant vector Ksp-cadherin-Gpx1-Kik1 laid foundations for investigations in establishing transgenic animal models, the over-expression of Gpx1 and Kikl in mammal kidney, and gene therapy for ischemia-reperfnsion injury during kidney transplantation.